Filipino-led Biotech Raises P10 Billion to Advance Revolutionary Cancer Research

InterVenn Biosciences recently announced the completion of a P10 Billion Series C financing from SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management. The fund will largely be allocated for the development and commercialization of Dawn, a blood-based test aimed at helping physicians appropriately match cancer patients to the im…